NEW YORK (GenomeWeb News) – Trovagene today said that it has entered into an R&D agreement with PerkinElmer Health Sciences to design an assay for evaluating a patient's risk of developing hepatocellular carcinoma.

The assay will be based on Trovagene's TrNA technology, the company said in a document filed with the US Securities and Exchange Commission, adding that both firms will jointly validate the assay and evaluate the possibility of combining the TrNA technology with PerkinElmer's technology for automation of nucleic acid isolation.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.